12.13
+0.33%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Qianjiang Yongan Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002365.SZ. It has been listed since 5 March 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥783.2m and net income of CN¥22.5m. At that date it held total assets of CN¥2.20bn and shareholders' equity of CN¥1.99bn.
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in the research, development, production and sales of taurine products. The company is headquartered in Qianjiang, Hubei. The company went IPO on 2010-03-05. The firm operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Mar 2010
- Employees
- 1,004
- Website
- chinataurine.com ↗
Leadership
Pay as last reported
- Mr. Yong ChenChairman of the Board, since 2024CN¥1.4m
- Mr. Shengjie XiongChief Financial Officer, Secretary of the Board
- Mr. Rengui HongGeneral Manager, Director, since 2024
- Mr. Zidi ChenExecutive Deputy General Manager, Director, since 2024
- Mr. Xiquan FangDeputy General Manager
- Mr. Zhihua WangDeputy General Manager
- Mr. Wei YeDeputy General Manager
- Ms. Yonghong DengSenior Management
- Mr. Wei DongSenior Management
- Mr. Shaobo LiSenior Management
- Ms. Qiong WuSenior Management
- Mr. Xiaohua GuoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company employs 1004 full-time staff members in Qianjiang.
- The Taurine Products segment drives core research and development activities.
- The Food Supplement segment handles import and sales of dietary supplements.
Weaknesses
- The Health Field segment focuses on equity investments rather than direct sales.
- The company operates primarily within the Chinese domestic market.
- Ethylene oxide manufacturing is limited to the Taurine Products segment.
Opportunities
- Expanding the import and sales of overseas dietary supplements globally.
- Increasing equity investments in the broader health-related field sector.
- Growing demand for taurine products in international markets.
Threats
- Fluctuations in the global market for taurine products affect revenue.
- Regulatory changes in China impact the pharmaceutical industry significantly.
- Competition in the dietary supplement segment may reduce market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.